Discounting health effects in pharmacoeconomic evaluations J. M. BosMaarten J. PostmaLieven Annemans Current Opinion 17 September 2012 Pages: 639 - 649
Price differentiation and transparency in the global pharmaceutical marketplace David B. Ridley Current Opinion 17 September 2012 Pages: 651 - 658
Evaluating health-related quality-of-life studies in paediatric populations Mirella De CivitaDean RegierCarlo A. Marra Review Article 17 September 2012 Pages: 659 - 685
The state of patient-reported outcomes in atrial fibrillation Karin CoyneMary Kay MargolisPeter Zimetbaum Review Article 17 September 2012 Pages: 687 - 708
Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information? Kun-Sei LeeWerner B. F. BrouwerHye-Won Koo Review Article 17 September 2012 Pages: 709 - 721
Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Bernd BrüggenjürgenDagmar SelimStefan N. Willich Original Research Article 17 September 2012 Pages: 723 - 731
Costs and medical care consequences associated with the diagnosis of peripheral arterial disease Kristen Migliaccio-WalleJ. Jaime CaroJudith A. O’Brien Original Research Article 17 September 2012 Pages: 733 - 742
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK Eduardo Carracedo-Martínez Correspondence 17 September 2012 Pages: 743 - 743
The authors’ reply Andrew MooreCeri PhillipsSimone Crespi Correspondence 17 September 2012 Pages: 743 - 744